Purpose: The aim of this study was to find the dose of agonistic 4-1BB monoclonal antibody (mAb) that results in optimal T cell activation. Methods: Cancer was induced in mice by an intrahepatic parenchymal injection of 1×10 5 cells of CT26 cells.
INTRODUCTION

2) Assessment of response
Subsets of four mice from each dosage group were sacrificed on days 14, 28, and 42 after the administration of CT26 cells. Livers and spleens were harvested from the sacrificed mice. Because it was not possible to obtain the weights of the cancer masses alone, liver weights included the cancer masses.
3) Flow cytometry analysis
Splenocytes were obtained from the mice through the mechanical dissociation of the spleen followed by lysis of 
4) Apoptosis detection assay
Annexin V was used to quantitate the percentage of cells within a population that were actively undergoing apop- 
5) Statistical analyses
Groups of data were compared using two-way ANOVA, a post hoc test, and the Kruskal-Wallis test (SPSS 17.0).
A P-value of less than 0.05 was considered statistically significant.
RESULTS
1) Liver weights
To investigate the role of 4-1BB the therapeutic effect of agonistic 4-1BB mAb in an experimental cancer model, cancer was induced in Balb/c mice. Liver size changed with an increasing dose of agonistic 4-1BB mAb and over time (Fig. 1) . Gross examination of the liver size revealed no increase when more than 20μg of agonistic 4-1BB mAb was used. However, an increase in liver size was seen for the control and at dose of 5μg and 10μg of agonistic 4-1BB mAb. The liver weight increased when 5μg of agonistic 4-1BB mAb was given, but did not increase at doses larger than 10μg (P＜0.05). In other words, 5μg
of agonistic 4-1BB mAb failed to show significant tumor suppression, whereas higher doses of agonistic 4-1BB mAb (10μg to 300μg) suppressed tumor growth and increase in liver weight to similar degree (Fig. 2) .
2) CD4 and CD8
Absolute cell numbers of CD4＋ and CD8＋ T cells (Fig. 3, 4) .
3) Apoptotic cell proportion
CD4/annexin V and CD8/annexin V peaked at 28 days in the high dose groups (100μg, 200μg, or 300μg of agonistic 4-1BB mAb) (Fig. 5 ). The absolute cell number for a dose of 300μg agonistic 4-1BB mAb was higher than that for the 100μg dose treatment (P＜0.05). The absolute CD4/CD25 cell population. The absolute cell numbers increased in the low dose (≤20μg) groups, but not in the high dose groups (≥100μg). Absolute cell numbers peaked on day 28 in the high dose groups and decreased by day 42. In contrast, the absolute cell numbers on day 42 were significantly higher than those at day 14 for doses of agonistic 4-1BB mAb (≤20μg; *P＜0.05).
number of CD4/annexin V cells was greater than that of CD8/annexin V cells (P＜0.05). The absolute cell number for each dose decreased at 42 days (Fig. 5 ).
4) Innate immunity
Patterns of change in CD11c and natural killer (NK) cells were comparable to those of the T cells (Fig. 6 ). The absolute cell numbers increased for the low dose agonistic 4-1BB mAb groups (5μg, 10μg, 20μg), but not for the high dose groups (100μg, 200μg, 300μg) . However, for CD11b cells, the absolute cell numbers for the low dose groups (5μg, 10μg, 20μg) peaked at 28 days and decreased at 42 days (Fig. 6A ). The absolute cell numbers for the high dose group (100μg, 200μg, 300μg) were all lower than those for the low dose group (Fig. 6 ).
DISCUSSION
The physiology and geography of T cell activation The anti-tumor effect of agonistic 4-1BB mAbs mainly We studied T cells in mice that were of the same age 
